In 2018,[7] Veralytics became a wholly-owned subsidiary of Merck & Co.[8] Viralytics stock is publicly traded on the ASX under the code VLA.
[13] Viralytics' is headquartered in the City Mutual Building, an art deco icon in the Sydney CBD located at 66 Hunter Street.
[15] Shafren et al. first published data showing that Cavatak could destroy malignant melanoma cells in the journal Clinical Cancer Research in January 2004.
[16] A June 2005 paper in the International Journal of Oncology showed that this effect worked as well for melanoma exhibiting a highly vascular phenotype.
[17] In April 2007, in a paper in the British Journal of Haematology, the Shafren lab showed that Cavatak could work in multiple myeloma[18] and over the next two years papers in The Prostate (May 2008)[19] and Breast Cancer Research and Treatment (January 2009)[20] suggested similar pre-clinical efficacy in prostate and breast cancer respectively.
In this trial, which was initiated in May 2007[21] but was not completed until 2009, all patients were given two Cavatak doses of the same size 48 hours apart into a single cutaneous melanoma lesion.
These results were presented at the May 2011 Annual Meeting of the American Society of Clinical Oncology, held that same year at Chicago.